125 related articles for article (PubMed ID: 38344757)
1. Development of a physiologically based pharmacokinetic model for levetiracetam in patients with renal impairment to guide dose adjustment based on steady-state peak/trough concentrations.
Wang R; Wang T; Han X; Chen M; Li S
Xenobiotica; 2024 Mar; 54(3):116-123. PubMed ID: 38344757
[TBL] [Abstract][Full Text] [Related]
2. Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment.
You X; Wu W; Xu J; Jiao Z; Ke M; Huang P; Lin C
J Clin Pharmacol; 2020 Aug; 60(8):999-1010. PubMed ID: 32090332
[TBL] [Abstract][Full Text] [Related]
3. Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment.
Wu W; Ke M; Ye L; Lin C
Eur J Clin Pharmacol; 2021 Jul; 77(7):989-998. PubMed ID: 33447912
[TBL] [Abstract][Full Text] [Related]
4. Dosage Adjustment for Ceftazidime in Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling.
Zhou J; You X; Ke M; Ye L; Wu W; Huang P; Lin C
J Pharm Sci; 2021 Apr; 110(4):1853-1862. PubMed ID: 33556385
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations.
Shen C; Shao W; Wang W; Sun H; Wang X; Geng K; Wang X; Xie H
CPT Pharmacometrics Syst Pharmacol; 2023 Jul; 12(7):1001-1015. PubMed ID: 37170680
[TBL] [Abstract][Full Text] [Related]
6. Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment.
Gao D; Wang G; Wu H; Ren J
Sci Rep; 2023 Sep; 13(1):16027. PubMed ID: 37749178
[TBL] [Abstract][Full Text] [Related]
7. Application of PBPK modeling in predicting maternal and fetal pharmacokinetics of levetiracetam during pregnancy.
Chen J; You X; Wu W; Guo G; Lin R; Ke M; Huang P; Lin C
Eur J Pharm Sci; 2023 Feb; 181():106349. PubMed ID: 36496167
[TBL] [Abstract][Full Text] [Related]
8. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations.
Toublanc N; Sargentini-Maier ML; Lacroix B; Jacqmin P; Stockis A
Clin Pharmacokinet; 2008; 47(5):333-41. PubMed ID: 18399714
[TBL] [Abstract][Full Text] [Related]
9. Levetiracetam pharmacokinetics in Japanese subjects with renal impairment.
Yamamoto J; Toublanc N; Kumagai Y; Stockis A
Clin Drug Investig; 2014 Nov; 34(11):819-28. PubMed ID: 25312351
[TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic Modeling and Dose Adjustment of Teicoplanin in Pediatric Patients With Renal Impairment.
Xu J; Lin R; Chen Y; You X; Huang P; Lin C
J Clin Pharmacol; 2022 May; 62(5):620-630. PubMed ID: 34761398
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetic Modeling of Lacosamide in Patients With Hepatic and Renal Impairment and Pediatric Populations to Support Pediatric Dosing Optimization.
Zhu X; Guo L; Zhang L; Xu Y
Clin Ther; 2024 Mar; 46(3):258-266. PubMed ID: 38369451
[TBL] [Abstract][Full Text] [Related]
12. A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model.
Mahmood I
Drugs R D; 2020 Dec; 20(4):377-387. PubMed ID: 33150526
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations.
Guo L; Zhu X; Zhang L; Xu Y
Ther Adv Drug Saf; 2023; 14():20420986231220222. PubMed ID: 38157240
[TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Pharmacokinetic Modelling of Glycopyrronium in Patients With Renal Impairment.
Higashimori M; Ishikawa K; Gillen M; Zhou D
J Pharm Sci; 2021 Jan; 110(1):438-445. PubMed ID: 32240691
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment.
Ye L; You X; Zhou J; Wu C; Ke M; Wu W; Huang P; Lin C
Front Pharmacol; 2022; 13():838599. PubMed ID: 36052120
[No Abstract] [Full Text] [Related]
16. A Physiologically Based Pharmacokinetic Model of Ertapenem in Pediatric Patients With Renal Impairment.
Ye L; Ke M; You X; Huang P; Lin C
J Pharm Sci; 2020 Sep; 109(9):2909-2918. PubMed ID: 32565352
[TBL] [Abstract][Full Text] [Related]
17. Simulation of febuxostat pharmacokinetics in healthy subjects and patients with impaired kidney function using physiologically based pharmacokinetic modeling.
Xu Y; Chen J; Ruan Z; Jiang B; Yang D; Hu Y; Lou H
Biopharm Drug Dispos; 2022 Aug; 43(4):140-151. PubMed ID: 35748093
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of Physiologically Based Pharmacokinetic Model of Levetiracetam to Predict Exposure and Dose Optimization in Pediatrics.
Shao W; Shen C; Wang W; Sun H; Wang X; Geng K; Wang X; Xie H
J Pharm Sci; 2023 Oct; 112(10):2667-2675. PubMed ID: 37023853
[TBL] [Abstract][Full Text] [Related]
19. Development of Physiologically Based Pharmacokinetic Model for Pregabalin to Predict the Pharmacokinetics in Pediatric Patients with Renal Impairment and Adjust Dosage Regimens: PBPK Model of Pregabalin in Pediatric Patients with Renal Impairment.
Ke C; You X; Lin C; Chen J; Guo G; Wu W; Ye L; Huang P
J Pharm Sci; 2022 Feb; 111(2):542-551. PubMed ID: 34706283
[TBL] [Abstract][Full Text] [Related]
20. Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.
Lobo ED; Heathman M; Kuan HY; Reddy S; O'Brien L; Gonzales C; Skinner M; Knadler MP
Clin Pharmacokinet; 2010 May; 49(5):311-21. PubMed ID: 20384393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
